Preferred stock:
5,000,000 shares authorized Series A Convertible Preferred stock, 11,984 shares designated; 0 and 9,856 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively
| | |
Common stock:
150,000,000 shares authorized;
6,338,320 and 3,251,970 shares issued and outstanding as of June 30, 2019 and December 31, 2018, respectively, and 23,792 and 1,758 shares to be issued as of June 30, 2019 and December 31, 2018, respectively
Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-005974/0001387131-19-005974.pdf
On October 31, 2019, the Company filed a Certificate of Change with the Nevada Secretary of State, which was effective November 1, 2019. Pursuant to the Certificate of Change, the Company effected a 1-for-10 reverse stock split of its issued and outstanding shares of common stock, $0.001 par value, whereby 15,717,402 outstanding shares of the Company’s common stock were exchanged for 1,575,246 shares of the Company’s common stock. In connection with the reverse stock split, the Company issued an additional 3,457 shares of the Company’s common stock due to rounding. Furthermore, pursuant to the Certificate of Change, the number of authorized shares of common stock was reduced from 150 million to 15 million. All per share amounts and number of shares in the condensed consolidated financial statements and related notes have been retroactively restated to reflect the reverse stock split.
Source: https://ir.tonixpharma.com/all-sec-filings/content/0001387131-19-008474/0001387131-19-008474.pdf
| | |